Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000963 Huadong Medicine Co.,Ltd.

Closed 07-24 15:00:00

28.58

-1.81

-5.96%

High30.37	Low28.56	Vol31.51M
Open30.00	D1 Closing30.39	Amplitude5.96%
Mkt Cap50.13B	Tradable Cap50.10B	Total Shares1.75B
T/O921.00M	T/O Rate1.80%	Tradable Shares1.75B
P/B2.07	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":28.58,"timestamp":1784876622000,"preClose":30.39,"halted":0,"volume":31511860,"delay":0,"changeRate":-0.0596,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"Closed","change":-1.81,"latestTime":"07-24 15:00:00","open":30,"high":30.37,"low":28.56,"amount":921000000,"amplitude":0.0596,"askPrice":28.58,"askSize":213,"bidPrice":28.57,"bidSize":865,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":30.39,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":33.43,"lowLimit":27.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":14.312901,"roe":"3.97%","epsLYR":1.9484,"committee":0.32915,"marketValue":50122000000,"turnoverRate":0.018,"status":1,"floatMarketCap":50101000000},"requestUrl":"/m/hq/s/000963/tweets","defaultTab":"tweets","newsList":[{"id":"1120367878","title":"Huadong Medicine Chairman Proposes Interim Dividend Plan for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1120367878","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120367878?lang=en_us&edition=fundamental","pubTime":"2026-07-20 12:01","pubTimestamp":1784520082,"startTime":"0","endTime":"0","summary":"An announcement from Huadong Medicine Co.,Ltd. (SZSE: 000963) reveals a proposal by the company's Chairman, Mr. Lv Liang.The proposal, made under the authority granted by the 2025 annual general...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000963","BK0183","BK0187","BK0188","BK0175","BK0196","LU1969619763.USD","LU2328871848.SGD","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652626122","title":"Huadong Medicine's Chairman Proposes Cash Dividend Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652626122","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652626122?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:58","pubTimestamp":1784519913,"startTime":"0","endTime":"0","summary":"BRIEF-Huadong Medicine's Chairman Proposes Cash Dividend PlanJuly 20 (Reuters)-Huadong Medicine Co Ltd000963.SZ:SAYS CHAIRMAN PROPOSES CASH DIVIDEND OF 3.5 YUAN ($0.5169) (INCLUDING TAX) PER 10 SHARES TO ALL SHAREHOLDERSSource textFurther company coverage:000963.SZ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nL4N43M09C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","000963","BK0183","LU2328871848.SGD","BK0187","BK0132","LU1969619763.USD","BK0175","BK0209","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650809945","title":"Huadong Medicine's Attributable Profit Jumps 9.6% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2650809945","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650809945?lang=en_us&edition=fundamental","pubTime":"2026-07-09 12:53","pubTimestamp":1783572811,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  attributable profit rose 9.6% to 1.00 billion yuan in the first half from 914.7 million yuan in the year-ago period, according to a Thursday filing with the Shenzhen bourse.Earnings per share at the drug maker increased 9.6% to 0.5715 yuan from 0.5213 yuan in the previous year.Operating revenue grew 4.2% year over year to 11.2 billion yuan from 10.7 billion yuan.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK0132","BK0175","000963","LU2328871848.SGD","BK0188","FCA","BK0183","BK0196","BK0187","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178671040","title":"Huadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1178671040","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178671040?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383921,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0187","BK0183","BK0209","LU1969619763.USD","LU2328871848.SGD","000963","BK0196","BK0188","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646822927","title":"Huadong Medicine's Unit Gets Registration Certificate for V30 Skin Treatment System","url":"https://stock-news.laohu8.com/highlight/detail?id=2646822927","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646822927?lang=en_us&edition=fundamental","pubTime":"2026-06-25 14:55","pubTimestamp":1782370535,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Viora, received a medical device registration certificate from China's National Medical Products Administration for its V30 Skin Treatment System, according to a Shenzhen bourse filing on Thursday.The skin treatment platform can be used with the V-IPL IPL handpiece, V-ST RF handpiece or the V-Nd:YAG laser handpiece to reduce wrinkles, treat vascular or pigmented lesions and acne, and remove hair.The pharmaceutical company's shares fell 1% during the afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU2328871848.SGD","BK0175","BK0188","BK0196","LU1969619763.USD","BK0187","BK0209","BK0132","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646822959","title":"Huadong Medicine Gets China Nod for Lymphoma Combo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2646822959","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646822959?lang=en_us&edition=fundamental","pubTime":"2026-06-25 14:52","pubTimestamp":1782370369,"startTime":"0","endTime":"0","summary":"Huadong Medicine  subsidiary Zhongmei Huadong obtained the approval of China's drug regulator to conduct clinical trials of HDM2005 in combination with PD-1 and AD chemotherapy for classical Hodgkin's lymphoma.The drug is already in trials for multiple hematologic and solid tumor indications in China and the U.S., according to a Thursday filing with the Shenzhen bourse.Shares of the drugmaker declined 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0188","BK0183","BK0175","LU1969619763.USD","BK0209","BK0187","BK0132","000963","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103413408","title":"Huadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30","url":"https://stock-news.laohu8.com/highlight/detail?id=1103413408","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103413408?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:54","pubTimestamp":1782298464,"startTime":"0","endTime":"0","summary":" Huadong Medicine Co.,Ltd. (SHE: 000963) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0209","BK0187","BK0183","BK0132","LU1969619763.USD","BK0188","LU2328871848.SGD","000963","IPOS","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139887422","title":"Mixed Performance: Huadong Medicine Navigates Innovation Realization and Sectoral Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=1139887422","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139887422?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:31","pubTimestamp":1781692276,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (Huadong Medicine) is experiencing a divergence across its four main business segments. The company's transition from a traditional pharmaceutical firm to a diversified...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK0209","000963","BK0132","LU1969619763.USD","BK0196","BK0187","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166546793","title":"Beneath the Surface of Huadong Medicine's Strong Figures: First Non-GAAP Profit Drop, High Receivables, and Cash Flow Strain","url":"https://stock-news.laohu8.com/highlight/detail?id=1166546793","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166546793?lang=en_us&edition=fundamental","pubTime":"2026-06-12 16:42","pubTimestamp":1781253763,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. presented seemingly solid annual results for 2025 and Q1 2026 reports, driven by record-high growth in its pharmaceutical manufacturing segment. However, behind the revenue...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0196","LU1969619763.USD","BK0188","BK0175","159399","BK0132","000963","BK0209","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442100","title":"Chinese Drug Regulator Accepts Huadong Medicine's Application for Facial Filler's New Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442100","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442100?lang=en_us&edition=fundamental","pubTime":"2026-06-10 17:44","pubTimestamp":1781084675,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Huadong Medicine's  application to add a new indication for a facial filler, according to a Shenzhen bourse filing on Wednesday.The Chinese drugmaker applied for the Ellansé S Injectable Polycaprolactone Microsphere Facial Filler to be used as an implant into the forehead to improve moderate to severe forehead contour defects.The company's shares jumped 5% at the close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","LU1969619763.USD","LU2328871848.SGD","000963","BK0209","BK0183","BK0132","BK0175","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118140430","title":"Huadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1118140430","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118140430?lang=en_us&edition=fundamental","pubTime":"2026-06-09 16:18","pubTimestamp":1780993115,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (ASX: 000963) has announced a significant regulatory development for one of its key medical aesthetic products.On June 8, 2026, the company's wholly-owned subsidiary,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","BK1574","BK0187","BK0196","BK0183","LU1969619763.USD","BK0132","000963","09996","BK0175","BK0188","BK1583","BK1100","BK0209","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638650075","title":"Beyond Next Ventures leads SCOHIA PHARMA private funding round raising JPY 3 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2638650075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638650075?lang=en_us&edition=fundamental","pubTime":"2026-05-28 15:13","pubTimestamp":1779952386,"startTime":"0","endTime":"0","summary":"Beyond Next Ventures led a private financing round for SCOHIA PHARMA that raised JPY 3 billion, announced May 28, 2026.SCOHIA PHARMA develops small- and medium-molecule drugs for metabolic, endocrine, cardiovascular diseases; founded in 2017 via a Takeda carve-out.Lead obesity and diabetes asset SCO-094 was out-licensed to Huadong Medicine; once-weekly formulation is in Phase 3 trials in China.In April 2026, SCOHIA PHARMA signed an exclusive worldwide license with Neurocrine for MC2R antagonist SCO-483 with milestones up to USD 550 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Next Ventures Inc published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7DfzMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2065170008.USD","LU0320765992.SGD","LU0823416689.USD","BK4139","LU2065169927.USD","BK0196","NBIX","LU0154245673.USD","LU1969619763.USD","LU2065171402.SGD","BK0175","LU0154245756.USD","LU0109394709.USD","BK0187","000963","LU2065171311.SGD","BK0209","BK0188","BK0132","LU2328871848.SGD","BK0183","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115332947","title":"Huadong Medicine's Subsidiary Gains NMPA Approval for Crohn's Disease Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1115332947","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115332947?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:08","pubTimestamp":1779354506,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received the \"Drug Registration Certificate\" and \"Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","BK4579","BK0183","BK4166","000963","BK4531","BK0209","LU0049112450.USD","LU1046422090.SGD","IPOS","BK0175","LU1235295612.USD","BK0187","LU1969619763.USD","LU2328871848.SGD","BK0196","BK0188","LX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761911","title":"Huadong Medicine's Unit Gets Nod to Trial HDM2017 for Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761911","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635761911?lang=en_us&edition=fundamental","pubTime":"2026-05-14 12:06","pubTimestamp":1778731595,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of HDM2017 for injection, according to a Shenzhen bourse filing on Thursday.The drug is used in combination with Fruquintinib for the treatment of advanced colorectal cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000963","LU2328871848.SGD","BK0183","BK0196","BK0132","LU1969619763.USD","BK0188","BK0209","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629183058","title":"Huadong Medicine's Attributable Profit Slips 2.8% in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2629183058","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629183058?lang=en_us&edition=fundamental","pubTime":"2026-04-24 15:03","pubTimestamp":1777014197,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) attributable profit fell 2.8% year over year to 3.41 billion yuan in 2025, according to a Friday filing with the Shanghai bourse.Operating revenue jumped 4.1% year over year to 43.6 billion yuan.Shares increased 3% during afternoon trading on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","LU1969619763.USD","LU2328871848.SGD","000963","BK0209","BK0188","BK0132","BK0175","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894454","title":"Huadong Medicine Registers New Aesthetics Product Variant in China; Shares Jump 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894454","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629894454?lang=en_us&edition=fundamental","pubTime":"2026-04-24 13:25","pubTimestamp":1777008337,"startTime":"0","endTime":"0","summary":"Huadong Medicine  has obtained a medical device registration certificate from China's National Medical Products Administration for a new variant of its Ellansé aesthetics product, according to a Shenzhen Stock Exchange filing on Friday.The newly approved Ellansé M-type is a Class III medical device for injection containing polycaprolactone microspheres for facial filling. It has been approved for market launch, said Huadong.The M-type variant is designed for the temporal region. Huadong has already been marketing its Ellansé S-type product in China since August 2021.Shares of the company rose 4% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","LU2328871848.SGD","BK0188","BK0175","BK0187","BK0209","LU1969619763.USD","BK0132","000963","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839123","title":"BRIEF-Huadong Medicine 2025 Net Profit Down 2.8% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839123","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629839123?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:07","pubTimestamp":1776946028,"startTime":"0","endTime":"0","summary":"BRIEF-Huadong Medicine 2025 Net Profit Down 2.8% Y/YApril 23 (Reuters) - Huadong Medicine Co Ltd 000963.SZ:SAYS Q1 NET PROFIT UP 9.6% Y/Y2025 NET PROFIT DOWN 2.8% Y/YSource textSource text 2Further company coverage: 000963.SZ (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL4N4161GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0209","BK0188","BK0196","LU1969619763.USD","BK0183","BK0175","000963","LU2328871848.SGD","BK0187","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627402812","title":"Huadong Medicine's Weight-Loss Drug Marketing Application Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2627402812","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627402812?lang=en_us&edition=fundamental","pubTime":"2026-04-15 16:34","pubTimestamp":1776242065,"startTime":"0","endTime":"0","summary":"Huadong Medicine  said China's drug administrator accepted its marketing application for semaglutide injection.The drug is used for long-term weight management in obese or overweight adults, according to a Wednesday filing with the Shenzhen bourse.Shares of the drugmaker closed 2% higher Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU1969619763.USD","BK0187","BK0175","LU2328871848.SGD","BK0196","BK0132","BK0188","BK0209","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118117","title":"CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118117?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:07","pubTimestamp":1775826431,"startTime":"0","endTime":"0","summary":"CARsgen annual report for 2025 flagged a shift into value realization, led by stronger commercialization of BCMA CAR-T zevorcabtagene autoleucel.Huadong Medicine placed 218 confirmed orders for zevor-cel during 2025.Claudin18.2 CAR-T satricabtagene autoleucel entered China NDA review in June 2025, with approval expected in first half of 2026.Strategy pivot accelerated toward off-the-shelf allogeneic CAR-T, with CT0596 and CT1190B positioned for IND clearance and Phase Ib trial starts in 2026 in China.Manufacturing footprint expanded in Shanghai, with a new Jinshan commercial base planned under a project capped at RMB 370 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDLch6MLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0209","BK1574","LU2328871848.SGD","BK1161","02171","000963","BK0175","BK1585","BK0196","LU1969619763.USD","BK0132","BK0183","BK0188","BK1587","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178382932","title":"Global First Recombinant Botulinum Toxin Type A Approved, Huadong Medicine Ushers in New Era","url":"https://stock-news.laohu8.com/highlight/detail?id=1178382932","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178382932?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:46","pubTimestamp":1774615613,"startTime":"0","endTime":"0","summary":"On March 27, 2026, Huadong Medicine Co.,Ltd. announced the approval of a new drug. According to the announcement, an injectable recombinant botulinum toxin type A (R&D code: YY001, brand name:...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","150259","LU2328871848.SGD","BK0175","BK0132","000963","BK0209","BK0196","BK0183","LU1969619763.USD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784902308356,"stockEarnings":[{"period":"1week","weight":-0.0491},{"period":"1month","weight":0.0508},{"period":"3month","weight":-0.1179},{"period":"6month","weight":-0.1764},{"period":"1year","weight":-0.2721},{"period":"ytd","weight":-0.2133}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0498},{"period":"6month","weight":-0.0627},{"period":"1year","weight":0.0822},{"period":"ytd","weight":-0.0232}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"84304人(较上一季度增加26.48%)","perCapita":"20793股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":"　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction